Variability of the positive predictive value of PI-RADS for prostate MRI across 26 centers: Experience of the society of abdominal radiology prostate cancer disease-focused panel

Antonio C. Westphalen, Charles E. McCulloch, Jordan M. Anaokar, Sandeep Arora, Nimrod S. Barashi, Jelle O. Barentsz, Tharakeswara K. Bathala, Leonardo K. Bittencourt, Michael T. Booker, Vaughn G. Braxton, Peter R. Carroll, David D. Casalino, Silvia D. Chang, Fergus V. Coakley, Ravjot Dhatt, Steven C. Eberhardt, Bryan R. Foster, Adam T. Froemming, Jurgen J. Fütterer, Dhakshina M. GaneshanMark R. Gertner, Lori Mankowski Gettle, Sangeet Ghai, Rajan T. Gupta, Michael E. Hahn, Roozbeh Houshyar, Candice Kim, Chan Kyo Kim, Chandana Lall, Daniel J.A. Margolis, Stephen E. McRae, Aytekin Oto, Rosaleen B. Parsons, Nayana U. Patel, Peter A. Pinto, Thomas J. Polascik, Benjamin Spilseth, Juliana B. Starcevich, Varaha S. Tammisetti, Samir S. Taneja, Baris Turkbey, Sadhna Verma, John F. Ward, Christopher A. Warlick, Andrew R. Weinberger, Jinxing Yu, Ronald J. Zagoria, Andrew B. Rosenkrantz

Research output: Contribution to journalArticlepeer-review

197 Scopus citations

Abstract

Background: Prostate MRI is used widely in clinical care for guiding tissue sampling, active surveillance, and staging. The Prostate Imaging Reporting and Data System (PI-RADS) helps provide a standardized probabilistic approach for identifying clinically significant prostate cancer. Despite widespread use, the variability in performance of prostate MRI across practices remains unknown. Purpose: To estimate the positive predictive value (PPV) of PI-RADS for the detection of high-grade prostate cancer across imaging centers. Materials and Methods: This retrospective cross-sectional study was compliant with the HIPAA. Twenty-six centers with members in the Society of Abdominal Radiology Prostate Cancer Disease-focused Panel submitted data from men with suspected or biopsy-proven untreated prostate cancer. MRI scans were obtained between January 2015 and April 2018. This was followed with targeted biopsy. Only men with at least one MRI lesion assigned a PI-RADS score of 2–5 were included. Outcome was prostate cancer with Gleason score (GS) greater than or equal to 3+4 (International Society of Urological Pathology grade group ≥2). A mixed-model logistic regression with institution and individuals as random effects was used to estimate overall PPVs. The variability of observed PPV of PI-RADS across imaging centers was described by using the median and interquartile range. Results: The authors evaluated 3449 men (mean age, 65 years 6 8 [standard deviation]) with 5082 lesions. Biopsy results showed 1698 cancers with GS greater than or equal to 3+4 (International Society of Urological Pathology grade group ≥2) in 2082 men. Across all centers, the estimated PPV was 35% (95% confidence interval [CI]: 27%, 43%) for a PI-RADS score greater than or equal to 3 and 49% (95% CI: 40%, 58%) for a PI-RADS score greater than or equal to 4. The interquartile ranges of PPV at these same PI-RADS score thresholds were 27%–44% and 27%–48%, respectively. Conclusion: The positive predictive value of the Prostate Imaging and Reporting Data System was low and varied widely across centers.

Original languageEnglish (US)
Pages (from-to)76-84
Number of pages9
JournalRADIOLOGY
Volume296
Issue number1
DOIs
StatePublished - Jul 2020

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint

Dive into the research topics of 'Variability of the positive predictive value of PI-RADS for prostate MRI across 26 centers: Experience of the society of abdominal radiology prostate cancer disease-focused panel'. Together they form a unique fingerprint.

Cite this